Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-371 + ivacaftor is an investigational combination therapy under development for the treatment of **primary ciliary dyskinesia** (PCD). VX-371 (code name P-1037) is formulated as an inhalation solution and acts as a small molecule agent to restore ciliary function, potentially improving mucociliary clearance. **Ivacaftor** (VX-770) is a small molecule **CFTR potentiator** that increases the probability of the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein channel opening, improving chloride ion transport across epithelial cells. The combination aims to enhance overall mucociliary function more effectively than either agent alone. Clinical studies have evaluated the safety and efficacy of inhaled VX-371 in combination with oral ivacaftor in subjects aged 12 years and older with diagnosed PCD[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VX-371 + ivacaftor.